Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Roivant Sciences Ltd. (Nasdaq: ROIV) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Bermuda-incorporated biopharmaceutical issuer with common shares listed on The Nasdaq Global Select Market, Roivant files annual reports, quarterly updates, current reports on Form 8-K, proxy statements and other disclosures that describe its business, governance, financial condition and material events.
Through Roivant’s filings, investors can review detailed information on its biopharmaceutical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as the activities of subsidiaries such as Priovant Therapeutics, Immunovant, Pulmovant and Genevant. Current reports on Form 8-K have been used to furnish press releases on quarterly financial results, to report positive Phase 3 VALOR data in dermatomyositis, to provide updates on Graves’ disease development at Immunovant, and to disclose authorization of common share repurchase programs.
Roivant’s periodic reports discuss consolidated research and development and general and administrative expenses, share-based compensation, gains and losses from transactions such as the sale of Telavant net assets and the sale of its equity interest in Dermavant, and income or loss from discontinued operations. The company’s definitive proxy statement on Schedule 14A describes its annual general meeting of shareholders, director elections, auditor ratification and advisory votes on executive compensation, and lays out governance and compensation policies.
On Stock Titan, Roivant filings are paired with AI-powered summaries designed to help readers interpret complex documents. Users can quickly see the key points from 10-K and 10-Q reports, understand the significance of 8-K disclosures, and locate information related to capital allocation, clinical programs and subsidiary activities. Form 4 and other ownership-related filings, when available, can be used to track insider transactions and equity incentives disclosed by the company.
Roivant Sciences Ltd. reported that President and Vant Chair Frank Torti had 160,035 common shares withheld on March 31, 2026 to cover tax obligations tied to previously granted RSUs. The issuer net settled these RSUs to satisfy applicable tax withholding, and Torti now directly holds 13,576,512 common shares.
Roivant Sciences Ltd. reported preliminary unaudited consolidated cash, cash equivalents and marketable securities of approximately $4.3 billion as of March 31, 2026. The company repurchased 3,956,362 common shares during the quarter for about $109.7 million, excluding fees and commissions.
Roivant announced a new seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris, adding a fourth late-stage indication alongside dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis. The FDA granted Priority Review to brepocitinib’s NDA in dermatomyositis, with a PDUFA target action date in Q3 2026.
The company also reported topline results from Immunovant’s two Phase 3 studies of batoclimab in thyroid eye disease, which did not meet the primary endpoint of ≥2mm proptosis responder rate at Week 24. Safety was consistent with prior data, and Immunovant plans to continue developing FcRn blocker IMVT-1402, including potentially registrational Graves’ disease studies with topline data expected in calendar year 2027.
Roivant Sciences CEO Matthew Gline exercised capped value appreciation rights and had shares withheld to cover taxes. On March 30, 2026, 2,178,150 vested CVARs were settled into 97,319 Common Shares, and a portion of these was net-settled to satisfy tax withholding obligations. On March 31, 2026, additional Common Shares from previously granted RSUs were also net-settled for tax withholding. After these compensation-related transactions, Gline directly held 17,025,890 Common Shares, indicating he retained a large equity position and that the dispositions were primarily for tax obligations rather than open-market trading.
Roivant Sciences Ltd. director and President & CIO Mayukh Sukhatme exercised equity awards and had shares withheld for taxes. On March 30, 2026, he exercised 1,306,889 Capped Value Appreciation Rights, which were settled into 58,391 Common Shares based on the closing share price that day.
The issuer then conducted net share settlements to cover tax obligations, withholding 29,809 Common Shares at $26.41 related to the CVAR settlement and 187,512 Common Shares at $27.70 tied to previously granted RSUs. After these non‑market tax-withholding dispositions, Sukhatme directly owned 18,677,617 Common Shares.
Roivant Sciences director Meghan Fitzgerald exercised stock options for 70,000 Common Shares at an exercise price of $8.80 per share and immediately sold the same 70,000 shares in an open-market transaction. The sale had a weighted average price of $27.45 per share, with individual trades executed between $27.32 and $27.80. Following these transactions, Fitzgerald directly holds 42,963 Common Shares, and the exercised option award is now fully vested and exhausted.
Roivant Sciences Ltd ownership disclosure: The Vanguard Group filed an amendment reporting 0 shares and 0% beneficial ownership of Roivant common stock. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538.
The filing is a routine ownership update reflecting disaggregated reporting by Vanguard entities rather than an acquisition or disposition of Roivant shares.
ROIV files a Form 144 proposing the sale of 70,000 common shares. The notice states the shares arise from an exercise of options under a registered plan and are to be sold through Morgan Stanley Smith Barney LLC on 03/26/2026. The filing lists proceeds of $1,921,458.00 and a reference number 715,701,137 on the form.
Roivant Sciences Ltd. CFO Richard Pulik reported a tax-related share disposition tied to restricted stock units (RSUs). The company net-settled 1,546 Common Shares on March 20, 2026 to satisfy applicable tax withholding obligations upon RSU vesting, rather than through an open-market sale.
After this tax-withholding transaction, Pulik directly holds 236,867 Common Shares. This type of F-code transaction is a routine administrative step associated with equity-based compensation, reflecting shares withheld for taxes instead of cash payment.
Roivant Sciences Ltd. Chief Accounting Officer Jennifer Humes reported a tax-related share disposition tied to restricted stock units. On the vesting and settlement of previously granted RSUs, the issuer net-settled 14,526 Common Shares at $27.70 per share to cover withholding obligations. After this non‑market transaction, Humes directly holds 97,729 Common Shares, indicating the event is compensation- and tax-driven rather than an open-market trade.
Roivant Sciences Ltd. filed an amended current report to attach the full Settlement Agreement between its subsidiary Genevant Sciences GmbH, Arbutus Biopharma Corp., Genevant Sciences Ltd. and Moderna, Inc. and ModernaTx, Inc.. The agreement, dated March 3, 2026, resolves all patent infringement litigation worldwide related to Genevant/Arbutus lipid nanoparticle delivery technology used in Moderna’s vaccines.
The complete Settlement Agreement is now included as Exhibit 10.1, with certain immaterial or confidential portions, exhibits and schedules omitted under Regulation S‑K provisions.